Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Phenanthroline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.58 |
| ▸ | CCR1 | P32246 | 5/20 | 0.94 |
| ▸ | CCR8 | P51685 | 5/20 | 0.94 |
| ▸ | LMNA | P02545 | 4/20 | 0.94 |
| ▸ | CCR5 | P51681 | 3/20 | 0.94 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.94 |
| ▸ | MMP2 | P08253 | 2/20 | 0.94 |
| ▸ | TSHR | P16473 | 2/20 | 0.94 |
| ▸ | MAPT | P10636 | 2/20 | 0.94 |
| ▸ | HTT | P42858 | 2/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.94 |
| ▸ | GMNN | O75496 | 1/20 | 0.94 |
| ▸ | TP53 | P04637 | 1/20 | 0.94 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.94 |
| ▸ | MMP9 | P14780 | 1/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.94 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenanthroline SCHEMBL29354015 | 0.97 | CCR1 (1.00) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL29367277 | 0.97 | CCR1 (1.00) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL8312 | 0.97 | CCR1 (1.00) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL8845760 | 0.97 | CCR1 (1.00) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL22982126 | 0.94 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL21300488 | 0.94 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL21044608 | 0.94 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL21060516 | 0.94 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL22462277 | 0.94 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E | |
| Phenanthroline SCHEMBL3812011 | 0.94 | CCR1 (0.94) | CCR1CCR8LMNACCR5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550252-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | Theravance, Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| EP-2523945-A1 | 1 - (2 - PHENOXYMETHYLPHENYL) PIPERAZINE COMPOUNDS AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | Theravance, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011119461-A1 | 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011085291-A1 | 1 - (2 - PHENOXYMETHYLPHENYL) PIPERAZINE COMPOUNDS AS SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| CN-1633224-B | Circuit board and electronic instrument | SEIKO EPSON CORP | 2010-08-11 | — | — | CN | disclosed |
| CN-1901244-A | Electro-optic device | SEIKO EPSON CORP (JP) | 2007-01-24 | — | — | CN | disclosed |
| CN-1251556-C | Electro-optical device and electronic apparatus | SEIKO EPSON CORP (JP) | 2006-04-12 | — | — | CN | disclosed |
| CN-1633224-A | Circuit board and electronic instrument | SEIKO EPSON CORP (JP) | 2005-06-29 | — | — | CN | disclosed |
| CN-1429054-A | Electro-optical device, method of manufacturing the same, circuit board, method of manufacturing the same, and electronic apparatus | SEIKO EPSON CORP (JP) | 2003-07-09 | — | — | CN | disclosed |